WEDNESDAY 15th JULY 2015 COMMENCING 09.30 AM
AT CARDIFF METROPOLITAN UNIVERSITY, LLANDAFF
CAMPUS, WESTERN AVENUE, CARDIFF CF5 2YB

AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Minutes of previous meeting
5. Chairman’s report (verbal update)
6. Appraisal 1: Full Submission
   Brimonidine (Mirvaso®) for the symptomatic treatment of facial
   erythema of rosacea in adult patients
7. Appraisal 2: Full Submission
   Darunavir/cobicistat (Rezolsta®) in combination with other
   antiretroviral medicinal products for the treatment of human
   immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years or
   older
8. Appraisal 3: Limited Submission
   Magnesium aspartate dihydrate (Magnaspartate®) for the
   treatment and prevention of magnesium deficiency, as diagnosed by
   a doctor. Magnaspartate is indicated in adults, children and
   adolescents aged from 2 years
9. Appraisal 4: Limited Submission
   Tacrolimus (Envarsus®) for prophylaxis of transplant rejection in
   adult kidney or liver allograft recipients. Treatment of allograft
   rejection resistant to treatment with other immunosuppressive
   medicinal products in adult patients
10. All Wales Prescribing Advisory Group – Feedback from meeting
    held 3rd June 2015

Enclosure

1/AWMSG/0715

2/AWMSG/0715

3/AWMSG/0715

4/AWMSG/0715

5/AWMSG/0715

6/AWMSG/0715

Appendices

Appendices

Appendices

Appendices
To protect commercial confidentiality the following appraisals will be held in private

11. Reappraisal following Independent Review  
    Pomalidomide (Imnovid®) in combination with dexamethasone for  
    the treatment of adult patients with relapsed and refractory multiple  
    myeloma who have received at least two prior treatment regimens,  
    including both lenalidomide and bortezomib, and have demonstrated  
    disease progression on the last therapy  

12. Reappraisal following Independent Review  
    Enzalutamide (Xtandi®) for the treatment of adult men with  
    metastatic castration-resistant prostate cancer who are  
    asymptomatic or mildly symptomatic after failure of androgen  
    deprivation therapy in whom chemotherapy is not yet clinically  
    indicated

The meeting will open to the public for the announcement of the recommendation

Date of next meeting: 16th September 2015 in Cardiff